Diagnosis of invasive fungal infections is often delayed, resulting in negative outcomes for many patients. Diagnostic delays are driven partially by failure to “think fungus” in appropriate scenarios. Additionally, the limitations of traditional fungal diagnostics also contribute to the delay in definitive fungal diagnosis. Recently, advances have been made in fungal diagnostics, including molecular techniques such as polymerase chain reaction (PCR) testing on various samples as well as metagenomic next-generation sequencing (mNGS) for RNA and DNA conducted on both blood and cerebrospinal fluid. Yet many questions remain in the clinical community about the performance characteristics of these advanced molecular tests in various populations and the interpretation of the test results to support clinical decision making. Join us for this 1-hour accredited activity, based on a town hall recorded on July 21, 2025, in which infectious diseases experts Drs Luis Ostrosky-Zeichner and Angel Desai discuss the appropriate use of advanced diagnostic techniques as part of an overall fungal diagnostic schema in pediatric hematology/oncology, intensive care, and immunocompromised host settings.
Release Date: September 16, 2025
Expiration Date: September 15, 2026
Estimated Time to Complete the Activity: 1 hrs
Media: Interactive, text-based activity
Upon completing this activity, the participant should be better able to:
This initiative is intended for infectious diseases physicians, critical care physicians, hospitalists, intensivists, surgeons, pathologists/clinical microbiologists, hematologists/oncologists, pharmacists, pediatric infectious disease specialists, transplant specialists, and other healthcare providers responsible for the diagnosis and management of invasive fungal infections.
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and Terranova Medica, LLC. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Partners designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The maximum number of hours awarded for this Continuing Nursing Education is 1 contact hour.
Partners designates this continuing education activity for 1.0 contact hours (0.10 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008073-9999-25-238-H01-P
Type of Activity: Application
Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.
Luis Ostrosky-Zeichner, MD, FACP, FIDSA, FSHEA, FECMM, CMQ
CONSULTANT, ADVISOR, OR SPEAKER: Scynexis, Melinta, GSK, Pulmocide, F2G, Basilea, Viracor Eurofins, Gilead
Angel Desai, MD, MPH
NOTHING TO DISCLOSE
The Terranova and Partners planners have no relevant financial relationship(s) to disclose with ineligible companies.
Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive CE credit, learners must follow these steps during the period from September 16, 2025 through September 15, 2026:
If you wish to receive acknowledgment for completing this activity, please follow the steps below:
You must receive a test score of at least 75% and respond to all evaluation questions to receive a certificate.
For Pharmacists: Upon successfully completing the post-assessment, your credit will be submitted to CPE Monitor. Please check your NABP account within thirty (30) days to make sure the credit has posted.
Internet
To participate, you will need access to a computer (either MAC or PC), tablet, or smart phone, with a Chrome (version 22.0.1229.94 or greater) web browser, Firefox (version 3.6 or greater) web browser or an Internet Explorer (version 8.0 or greater) web browser, JavaScript enabled, connected to the Internet (high speed connection preferred).
Terranova Medica, LLC, and Partners are committed to protecting the privacy of those who choose to participate in activities on funguscme.org. This information below describes our security policies for safeguarding personal information as well as the rationale for collection and use of personal information.
Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.
Collection and use of personal information
Terranova Medica, LLC, and Partners do not transfer, sell, or share personal information with outside parties. We will not disclose the information unless required in a legal proceeding.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
There is no fee for this activity.
Jointly provided by Partners and Terranova Medica, LLC.
MSGERC is providing content and distribution support.
This activity is supported by an independent educational grant from Karius.
For further information, contact Tom Davis by email (tdavis@terranovamedica.com).
For additional information about the accreditation of this activity, visit https://partnersed.com.
Copyright © 2025 PARTNERS and Terranova Medica, LLC.
